Allogene Therapeutics, Inc. (ALLO) shares jumped 48.90 percent, gaining $1.33 to $4.05 on Monday, after promising interim data from its ALPHA3 trial evaluating its CAR-T therapy cema-cel in lymphoma patients.
The stock is currently trading at $4.05 compared with its previous close of $2.72, after opening at $4.08 on the Nasdaq. Shares traded between $3.55 and $4.09 during the session, with volume surging to 34.94 million shares, well above the average daily volume of 5.83 million.
The company reported that 58.3 percent of patients treated with cema-cel achieved molecular residual disease clearance, with significant reductions in circulating tumor DNA levels compared to observation. The study, conducted in collaboration with Natera, Inc., suggests the therapy could help delay or prevent relapse in large B-cell lymphoma patients. Allogene's 52-week range is $0.86 to $4.09.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.